Pacific EdgeASX:PEB -6.00%46 PS Ratio is 21.36 as of Jul. 04, 2026, which is 20% below its 10-year median of 26.69. GuruFocus rates ASX:PEB with a GF Score™ of 46/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Pacific Edge ranks worse than 94.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pacific Edge's share price is A$0.235.
Pacific Edge's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.01. Hence, Pacific Edge's PS Ratio for today is 21.36.
Warning Sign:
Pacific Edge Ltd stock PS Ratio (=25) is close to 3-year high of 25.83.
The historical rank and industry rank for Pacific Edge's PS Ratio or its related term are showing as below:
ASX:PEB'
s PS Ratio Range Over the Past 10 Years
Min: 2 Med: 26.69 Max: 152.5
Current: 23.5
During the past 13 years, Pacific Edge's highest PS Ratio was 152.50. The lowest was 2.00. And the median was 26.69.
ASX:PEB's PS Ratio is ranked worse than 94.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.825
vs ASX:PEB: 23.50
Pacific Edge Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Pacific Edge was -55.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -20.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 7.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.70% per year.
During the past 13 years, Pacific Edge's highest 3-Year average Revenue per Share Growth Rate was 44.20% per year. The lowest was -26.30% per year. And the median was 16.30% per year.
Back to Basics: PS Ratio
Pacific Edge (ASX:PEB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Pacific Edge PS Ratio Related Terms
Pacific Edge PS Ratio Historical Data
* Premium members only.
The historical data trend for Pacific Edge's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Pacific Edge's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Edge PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pacific Edge's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pacific Edge's PS Ratio for today is calculated as
Pacific Edge's Share Price of today is A$0.235.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pacific Edge's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pacific Edge (ASX:PEB) has a PS Ratio of 21.36 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pacific Edge and its competitors. This is 20% below median its historical median of 26.69. Over the past decade, Pacific Edge's PS Ratio has ranged from 2.00 to 152.50. According to the industry distribution chart, Pacific Edge ranks #189 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 94.5%.
Is Pacific Edge's PS Ratio too high?
Pacific Edge's current PS Ratio of 21.36 is 20% below median its 10-year median of 26.69. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 152.50. The Medical Diagnostics & Research industry median PS Ratio is 2.83. Pacific Edge's value of 21.36 is 656.1% above this industry median. Based on the distribution chart, Pacific Edge ranks #189 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pacific Edge has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #189 out of 200 companies for PS Ratio. This places Pacific Edge in the lower half of its industry. The industry median PS Ratio is 2.83. Pacific Edge's value of 21.36 is 656.1% above this benchmark. Historically, Pacific Edge's own PS Ratio has ranged from 2.00 to 152.50 over the past decade. While the company's 10-year median is 26.69 vs. the industry median of 2.83, Pacific Edge has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.83, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Edge's current PS Ratio of 21.36 is 656.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pacific Edge and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Edge's current PS Ratio is 21.36, which is 20% below median its own 10-year median of 26.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.24 — trading 370% above its estimated fair value. The current PS Ratio is 21.36, which is 20% below median its 10-year median of 26.69 and 656.1% above the Medical Diagnostics & Research industry median of 2.83. Pacific Edge's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current PS Ratio is 21.36 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Edge (ASX:PEB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued.
The current stock price of A$0.24 is trading 370% above its estimated GF Value™ of A$0.05.
GuruFocus considers Pacific Edge to be Significantly Overvalued.
Key valuation signals for ASX:PEB:
PS Ratio: 21.36 (20% below median its 10-year median of 26.69)
GF Value™: A$0.05 vs. price of A$0.24 (370% above fair value)
Industry Position: 656.1% above the Medical Diagnostics & Research median (#189 of 200)
No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
46GF Score
Get the complete analysis for ASX:PEB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PEB has been successfully added to your 
